GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Over the past year, the GSK (LSE: GSK) share price has lagged behind the FTSE 100, falling 14% versus the Footsie’s gain of ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

GSK Pharma had reported a consolidated net profit of Rs 230 crore for Q3 FY25. This marks a significant surge of nearly 400 ...

Dr. Juliet Addo, Academic Engagement Director for Ghana and Head of the Africa Open Lab at GSK, has reaffirmed the importance ...